---
title: 'BRCA Mutation Testing in Men with Metastatic Castration-Resistant Prostate
  Cancer: Practical Guidance for Australian Clinical Practice'
date: '2025-01-18'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39825869/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20250118170356&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: Some patients with metastatic castration-resistant prostate cancer (mCRPC)
  possess germline or acquired defects in the DNA damage repair (DDR) genes BRCA1
  and BRCA2. Tumors with BRCA mutations exhibit sensitivity to poly-ADP ribose polymerase
  inhibitors (PARPi) such as olaparib and rucaparib. As a result, molecular diagnostic
  testing to identify patients with BRCA mutations eligible for the PARPi therapy
  has become an integral component of managing patients with mCRPC. There are ...
disable_comments: true
---
Some patients with metastatic castration-resistant prostate cancer (mCRPC) possess germline or acquired defects in the DNA damage repair (DDR) genes BRCA1 and BRCA2. Tumors with BRCA mutations exhibit sensitivity to poly-ADP ribose polymerase inhibitors (PARPi) such as olaparib and rucaparib. As a result, molecular diagnostic testing to identify patients with BRCA mutations eligible for the PARPi therapy has become an integral component of managing patients with mCRPC. There are ...